Evaluating dose-limiting toxicities of MDM2 inhibitors in patients with solid organ and hematologic malignancies: a systematic review of the literature
L Pi, J Rooprai, DS Allan, H Atkins, C Bredeson… - Leukemia Research, 2019 - Elsevier
Introduction Mouse double minute 2 protein (MDM2), a negative regulator of the p53 tumour
suppressor gene, is frequently amplified in malignancies. MDM2 antagonists have shown
efficacy in treating malignancies with MDM2 overexpression and can overcome
chemoresistance in acute myeloid leukemia. We systematically evaluated the safety profile
of MDM2 inhibitors in the treatment of solid organ and hematologic malignancies. Materials
and Methods We searched Medline and EMBASE from January 1947 to November 2018 for …
suppressor gene, is frequently amplified in malignancies. MDM2 antagonists have shown
efficacy in treating malignancies with MDM2 overexpression and can overcome
chemoresistance in acute myeloid leukemia. We systematically evaluated the safety profile
of MDM2 inhibitors in the treatment of solid organ and hematologic malignancies. Materials
and Methods We searched Medline and EMBASE from January 1947 to November 2018 for …